Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6371293 | 1.00 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2670823 | 1.00 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL398332 | 0.97 | — | — | |
| SCHEMBL398333 | 0.97 | — | — | |
| SCHEMBL398511 | 0.97 | — | — | |
| SCHEMBL637612 | 0.95 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5770258 | 0.95 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5831543 | 0.95 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1650265 | 0.91 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1297555 | 0.89 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4303277-A1 | ANTIFOULING COATING COMPOSITION | Nitto Kasei Co., Ltd. (JP) | 2024-01-10 | — | — | EP | disclosed |
| CN-116981742-A | Antifouling coating composition | 日东化成株式会社 | 2023-10-31 | — | — | CN | disclosed |
| WO-2022186143-A1 | ANTIFOULING COATING COMPOSITION | 日東化成株式会社 | 2022-09-09 | — | — | WO | disclosed |
| US-9359297-B2 | Spirolactam derivatives and uses of same | H. LUNDBECK A/S (DK) | 2016-06-07 | — | — | US | disclosed |
| US-9359297-B2 | Spirolactam derivatives and uses of same | H. LUNDBECK A/S (DK) | 2016-06-07 | — | — | US | disclosed |
| US-9359297-B2 | Spirolactam derivatives and uses of same | H. LUNDBECK A/S (DK) | 2016-06-07 | — | — | US | disclosed |
| US-20140194424-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2014-07-10 | — | — | US | disclosed |
| US-20140194424-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2014-07-10 | — | — | US | disclosed |
| US-20140194424-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2014-07-10 | — | — | US | disclosed |
| EP-2493304-B1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | LUNDBECK & CO AS H (DK) | 2014-02-26 | — | — | EP | disclosed |
| WO-2011053575-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011053575-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-05-05 | — | — | WO | disclosed |
| US-20110098299-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-04-28 | — | — | US | disclosed |
| US-20110098299-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-04-28 | — | — | US | disclosed |
| US-20110098299-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-04-28 | — | — | US | disclosed |
| EP-1858857-B1 | AZABICYCLOALKANE DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | LILLY CO ELI (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20080261999-A1 | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-23 | — | — | US | disclosed |
| US-20080261999-A1 | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-23 | — | — | US | disclosed |
| EP-1858857-A1 | AZABICYCLOALKANE DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | Eli Lilly & Company (US) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006096358-A1 | AZABICYCLOALKANE DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261999-A1 | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists | CHRNA1, CHRNA7, CHRNB1 | CHRNB2 9/4885CHRNA4 12/4885CHRNB4 16/4885 |
| US-20140194424-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | REN, AGTR1, PDE6D | CHRNB2 3760/4885CHRNA4 3012/4885CHRNB4 3694/4885 |
| US-20110098299-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | REN, AGTR1, PDE6D | CHRNB2 3760/4885CHRNA4 3012/4885CHRNB4 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.